Article

Simeprevir Responsible for Deaths in Japanese Hepatitis C Patients

A spike in the blood bilirubin levels resulting in hepatic dysfunction and/or renal impairment was determined as the cause of death.

Sovriad (simeprevir sodium) was launched in Japan in December 2013. Of an estimated 18,900 patients taking the medication for hepatitis C infection, 3 deaths have been reported till October 2014. Hepatic and or renal impairement resulting from a significant increase in blood bilirubin levels was identified as the cause of death. The Pharmaceutical and Medical Devices Agency in Japan subsequently issued a "Dear Healthcare Professional Letter" and also asked Janssen to update the Warnings Subsection in the Precautions Section within the label.

Link to the letter issued by PMDA: http://bit.ly/1waEwBf

Related Videos
John Michael O'Brien, PharmD, MPH
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
Richard J. Nowak, MD, MS, Yale School of Medicine
4 experts are featured in this series.
Naim Alkhouri, MD
Christine Funke, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo